Cost-Effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: A hospital-based perspective from Malaysia

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7701-7706

  Keat, Chan Huan ^a   Ghani, Norazila Abdul ^a  

^a HOSPITAL SULTANAH BAHIYAH   (Malaysia)

Author keywords

CINV; Cost effectiveness; Granisetron; Low emetogenic; Malaysia

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; METOCLOPRAMIDE;

ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FOLLOW UP; HUMAN; MALAYSIA; NAUSEA; NEOPLASM; PROGNOSIS; RETROSPECTIVE STUDY; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; GRANISETRON; HUMANS; MALAYSIA; METOCLOPRAMIDE; NAUSEA; NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; VOMITING;

EID: 84893430104     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7701     Document Type: Article

References (26)

1. Aleyasin A, HanafiS, Saffarieh E, et al (2012). Efficacy of generic granisetron vs Kytril® for PONV in major gynecological operations: a randomized, double-blind clinical trial. Iranian J Pharm Res, 11, 1059-64.
2. Almazron S and Alnaim L (2012). Evaluation of adherence to chemotherapy-induced nausea and vomiting guidelines. An observational study. J Cancer Therapy, 3, 613-20.
3. Annemans L, Strens D, Lox E, et al (2008). Cost-effectiveness analysis of aprepitant in the prevention of chemotherapyinduced nausea and vomiting in Belgium. Support Care Cancer, 16, 905-15.
4. Ballatori E, Roila F, Berto P, et al (1994). Cost and costeffectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics, 5, 227-37.
5. Burmeister H, Achi S, Studer C, et al (2012). Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supp Care Cancer, 20, 141-7.
6. Chan HK, Phua G, Kassim MS, et al (2013). Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy? Asian Pac J Cancer Prev, 14, 469-73.
7. Colayco DC and Hay J (2010). Cost-effectiveness of serotonintype 3 receptor antagonists for chemotherapy-induced emesis in non-small cell lung cancer patients receiving cisplatinbased chemotherapy. Value Health, 13, 41.
8. Cox F and Hirsch J (1993). Ondansetron: a cost-effective advance in anti-emetic therapy. Oncol, 50, 186-90.
9. Cunningham D, Gore M, Davidson N, et al (1993). The real costs of emesis-an economic analysis of ondansetron versus metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer, 29, 303-6.
10. Erntoft S (2011). Pharmaceutical priority setting and the use of health economic evaluations: a systematic literature review. Value Health, 14, 587-99.
11. Ettinger DS, Armstrong DK, Barbour S, et al (2012). Antiemesis. JNCCN, 10, 456-85.
12. Hassali MA, Thambyappa J, Nambiar S, et al (2013). TRIPS, Free Trade Agreements and the Pharmaceutical Industry in Malaysia. In "The New Political Economy of Pharmaceuticals: Production, Innnovation and TRIPS in the Global South", Eds Lofgren H and Williams OD. Palgrave Macmillan, Basingstoke pp 152-66.
13. Humphreys S, Pellissier J, Jones A (2013). Cost-effectiveness of an aprepitant regimen for prevention of chemotherapyinduced nausea and vomiting in patients with breast cancer in the UK. Cancer Manag Res, 5, 215-24.
14. nd edition. Ministry of Health, Kuala Lumpur, 75-8.
15. Jordan K, Hinke A, Grothey A et al (2007). A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer, 15, 1023-33.
16. Jordan K, Schmoll HJ, Aapro MS (2007). Comparative activity of antiemetic drugs. Oncol Hemato, 61, 162-75.
17. Koeller JM, Aapro MS, Gralla RJ, et al (2002). Antiemetic guidelines: creating a more practical treatment approach. Supp Care Cancer, 10, 519-22.
18. Kris MG, Hesketh PJ, Herrstedt J, et al (2005). Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supp Care Cancer, 13, 85-96.
19. Lordick F, Ehlken B, Ihbe-Heffinger A, et al (2007). Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer, 43, 299-307.
20. Lopes G, Burke T, Pellissier J, et al (2012). Aprepitant for patients receiving highly-emetogenic chemotherapy: an economic analysis for Singapore. Value Health Regional Iss, 1, 66-74.
21. Marshall DA and Hux M (2009). Design and analysis issues for economic analysis alongside clinical trials. Med Care, 47, 14-20.
22. Moore S, Tumeh J, Wojtanowski S, et al (2007). Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health, 10, 23-31.
23. Pharmacy Services Division Malaysia (2011). Drug Formulary. Ministry of Health, Kuala Lumpur pp 37.
24. Rothermel C (2013). What is health economics and outcome research? A primer for medical writers. Am Med Writers Assoc J, 28, 98-104.
25. Uyl-de Groot CA, Wait S, Buijt I (2000). Economics and healthrelated quality of life in antiemetic therapy: recommendations for trial design. Eur j Cancer, 36, 1522-35.
26. Yonemura M, Katsumata N, Hashimoto H, et al (2009). Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial. Jpn J Clin Oncol, 39, 443-8.